Long-acting reversible contraception, such as hormonal and non-hormonal intrauterine devices (IUDs) and hormonal implants, have been proven safe and effective for adolescent patients.
Several questions remain regarding the effect of COVID-19 infection and hypercoagulation in the management of patients taking oral contraceptives, estrogen therapy, and patients who are pregnant.
The permanent birth control device Essure is associated with higher rates of chronic lower abdominal or pelvic pain and abnormal uterine bleeding compared with tubal ligation.
More than 70,000 US women could be left without cost-free birth control after the Supreme Court upheld a Trump administration policy change that permits some employers to refuse to provide contraceptive coverage on religious or moral grounds.
For women with premature ovarian insufficiency, continuous use of combined oral contraceptives is associated with increased BMD, similar to that seen with high-dose hormone therapy.
The novel combined oral contraceptive pill includes estetrol 15mg (E4) and drospirenone 3mg (DRSP).
Use of combined hormonal contraceptives is associated with reduced efficacy of weight-loss interventions after initial weight loss.
The FDA Phexxi™ (lactic acid, citric acid and potassium bitartrate; Evofem Biosciences) vaginal gel for the prevention of pregnancy in females of reproductive potential for use as an on-demand method of contraception.
The FDA has updated its “Problems Reported with Essure” webpage to include medical device reports received in 2019.
A narrative review summarizes recent data on the pathophysiology, epidemiology, and burden of disease and treatment of menstrual migraine.
